Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Endocrine Neoplasia Type 2a × GSK3352589 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Endocrine Neoplasia Type 2a 1 Irritable Bowel Syndrome 1

Interventions

veliparib 1 vandetanib 1 pralsetinib 1 alectinib 1 Temozolomide 1 Sorafenib 1 Liquid Biopsy 1 GSK3352589 1 Crizotinib 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03154086 2019-08-09

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

GlaxoSmithKline

Phase 1 Completed

68 enrolled 80 charts

Multiple Endocrine Neoplasia Type 2a, Irritable Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡